Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Novel Toll-Like Receptor 7 Agonist Suppresses Replication of Hepatitis B Virus in Chimps

By BiotechDaily International staff writers
Posted on 08 May 2013
An experimental low molecular weight drug that activates the protein Toll-Like Receptor 7 on cells of the immune system was found to suppress viral replication and delay progression of liver disease in chimpanzees chronically infected with hepatitis B virus (HBV).

Toll-Like Receptor 7 normally recognizes invading viruses and signals the immune system to suppress viral replication via the innate immune response and to kill infected cells via the adaptive immune response. The experimental drug GS-620, developed by the biopharmaceutical company Gilead Sciences (Foster City, CA, USA) is a potent and selective orally active small molecule agonist of Toll-like receptor 7.

Investigators from Gilead Sciences and colleagues at Texas Biomedical Research Institute's Southwest National Primate Research Center (San Antonio, USA) administered GS-9620 was to HBV-infected chimpanzees every other day for four weeks and, after a one-week rest, for an additional four weeks at a higher dosage. They measured viral load in plasma and liver samples, the pharmacokinetics of GS-9620, and the following pharmacodynamics parameters: interferon-stimulated gene expression, cytokine and chemokine levels, lymphocyte and natural killer cell activation, and viral antigen expression. Clinical pathology parameters were monitored to determine the safety and tolerability of GS-9620.

Results published in the February 14, 2013, online edition of the journal Gastroenterology revealed that short-term oral administration of GS-9620 provided long-term suppression of serum and liver HBV DNA. Serum levels of HBV surface antigen, HBV e antigen, and numbers of HBV antigen-positive liver cells were reduced as liver cell apoptosis increased. GS-9620 administration induced production of interferon-alpha and other cytokines and chemokines, and activated interferon-stimulated genes, natural killer cells, and lymphocyte subsets.

"This GS-9620 therapy represents the first conceptually new treatment for HBV in more than a decade, and combining it with the existing antiviral therapy could be transformative in dealing with this disease," said first author Dr. Robert E. Lanford, a virologist and immunologist at the Texas Biomedical Research Institute. "This is an important proof-of-concept study demonstrating that the therapy stimulates the immune system to suppress the virus and eliminate infected liver cells. One of the key observations was that the therapy continued to suppress virus levels for months after therapy was stopped."

Related Links:
Gilead Sciences
Texas Biomedical Research Institute


Channels

Genomics/Proteomics

view channel
Image: Pluristem technicians produce PLacental eXpanded (PLX) cells in the company\'s state-of-the-art facility (Photo courtesy of Pluristem Therapeutics).

Placental Cells Secrete Factors That Protect Nerves from Ischemic Damage

Cells derived from placenta have been found to protect PC12 cells—rat-derived cells that behave similarly to and are used as stand-ins to study human nerve cells—in a culture-based ischemic stroke model.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.